Press Release
Envoys to China visit Xiamen to help the World Heritage Convention
The World Heritage Conference is about to be held. Fujian is ready to organize the conference at a high level to better show the world the Chinese style and tell the Fujian story. At the invitation of the Ministry of Foreign Affairs, 22 foreign envoys were in Fujian from July 13th to 17th. They went to Xiamen, Longyan, Ningde, Fuzhou and other places to visit the Gutian conference site, inspect Ningde’s Xiaqi village, etc., to understand the economic and social development of our province. 22 foreign envoys arrived in Fujian. At the first stop, they came to Xiamen, known as the “Sea Garden”. The envoys admired the achievements made in the development of the Xiamen Special Economic Zone.

Visit the Yundang Academy to understand the practice and results of ecological governance and protection
After getting off the plane on July 14, the envoys went straight to Yundang Academy to learn about the practices and results of the ecological management and protection of Yundang Lake. Somalia’s ambassador to China, Awale Ali Kurane, also took notes seriously. The comprehensive management of Yundang Lake has promoted the black and smelly waters and the extinct fish and shrimps of Yundang Lake to become the “Xiamen City Meeting Room” with clear waters and green shores and the fragrance of birds and flowers. It has become a good place for citizens to relax. “I really appreciate Xiamen’s achievements in balancing economic development and environmental protection, which are also closely related to Xi Jinping’s thoughts on ecological civilization.” Samoa’s ambassador to China, Tapsaray Toomata, said Xiamen’s experience It is worth learning and learning from all countries. He who has been to Xiamen before has witnessed the changes in Xiamen with his own eyes: “The city is getting more and more beautiful, and its development is getting better and better. I also heard that Xiamen is an immigrant city. I believe that it can attract so many people and it is naturally unique. Charm.”
Set foot on Gulangyu Island and revel in the unique cultural atmosphere here
Afterwards, the envoys took the “Lujiang 99” passenger ship to visit the scenery on both sides of the Lujiang River and were excited about their upcoming visit to Gulangyu, the Museum of Architecture of the World. The Minister of the Syrian Embassy in China, Bruhan Al Khatib, has not put down his phone, and recorded video after video, “I will send these videos to my friends in various countries to let them know what a beautiful city Xiamen is. .” Set foot on Gulangyu Island, this is a cultural tour of Xiamen. Visiting the Gulangyu Historical and Cultural Exhibition Hall, Shuzhuang Garden, walking through the streets to the homes of local residents to listen to family concerts… The compact and substantial itinerary allowed the envoys to fully indulge in the unique cultural atmosphere of Gulangyu. “This afternoon was very beautiful. I fully felt Xiamen’s great emphasis on the protection of cultural heritage and its unremitting efforts in the inheritance of historical and cultural heritage.” Shang Mugan, Minister of the Malaysian Embassy in China, said that Xiamen is an important place for cultural heritage protection.

The charm of Xiamen is everywhere
Private envoys, just like many ordinary tourists who come to Xiamen, also like to “take freely”, but compared to other tourists, they are more obsessed with digging Xiamen’s local culture. For example, knowing that the sweet-scented osmanthus tree in Yundang Academy has a good meaning in traditional Chinese culture, the envoys named it “Lucky tree” and immediately triggered a wave of group photos. They appreciate Xiamen’s rapid development while retaining its own characteristics. There were also some interesting details at the scene. For example, the Mauritian ambassador to China Wang Chunwan wore a Tang suit, which stood out among the envoys. As a descendant of Chinese descent, he has a natural kindness to China, and this is also his fourth visit to Fujian. He said that Xiamen makes him feel particularly cordial because he has the same blue sea and blue sky as Mauritius. And Tapsaray Toomata, who has been to Xiamen many times, misses Xiamen’s sunshine and seafood in his heart. He said that Xiamen is one of his favorite Chinese cities. The moment he landed from rainy Beijing to sunny Xiamen, he really felt very good, “and I can eat Xiamen’s seafood again.”
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot
Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.
AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.
The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“
Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.
“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“
The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.
Media Contact
Company: AI Labs
Contact: Media Team
Email: ryan@academic-labs.org
Website: https://ai-labs.live/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.
The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.
The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.
Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.
Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.
Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.
More Information About Povorcitinib Phosphate Tablets
Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.
A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).
About CMS
CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.
CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.
CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.
Reference
1、China Insights Consultancy (CIC) report
2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
ONAR’s Largest Acquisition Closed With Two Days Left in Q3
NYC, New York, November 19th, 2026, FinanceWire
ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.
Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.
What Advertise Purple brings to ONAR
The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.
ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.
Why the Nasdaq application matters
ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.
At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.
That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.
For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.
About ONAR Holding Corporation
ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.
Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.
Learn more at https://www.onar.com/
Contact
President
Craig Fischer
ValueCorp
cf@valuecorptrading.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Midwest Ragdolls Explains Why Playful Kitten Biting Is Often Misunderstood
-
Press Release2 days ago
OiLChef Wins Restaurant Solution of the Year Award at 2026 Restaurant & Takeaway Innovation Expo
-
Press Release1 week ago
ARCPE Holding, LLC Highlights the Importance of Understanding Local Real Estate Market Conditions
-
Press Release5 days ago
IntelliVIX Wins Two CES 2027 Innovation Awards, Showcasing Global Competitiveness in Safety AI
-
Press Release7 days ago
Red Banyan CEO Evan Nierman Leads High-Stakes Communications Workshop at NASDDDS Annual Conference
-
Press Release5 days ago
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
Press Release1 week ago
Dasher Personalized Running Highlights Personalized Half Marathon Training Plans Focused on Injury Prevention and Sustainable Progress
-
Press Release5 days ago
Eurotrace net Unveils New Blockchain Intelligence Research Initiative
